Agilent Technologies has launched a new system aimed at enhancing flow cytometry processes.
Agilent Technologies Inc has introduced its NovoStation Sample Preparation System, designed to automate workflows in flow cytometry. This advancement is set to improve efficiencies in sample preparation, a crucial step in various laboratory applications. The stock closed at US$167.69, reflecting a year-to-date increase of about 25% and a 1-month increase of 16.1%.
Investor takeaway: Agilent's latest product launch shows its commitment to innovation in the healthcare sector.
Advertisement
Agilent Technologies Inc
A.US
Market cap
$43.34B
P/E
29.7x
Div. yield
0.67%
Div. / share
$1.01
52W high
$163.75
52W low
$108.14
Beta
1.24
Analyst Price Targets
Based on 17 analysts covering A · as of Sep 17, 2026
Consensus
Buy4.41 / 5.00
Avg. Target
C$174.95
Current Price
—
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Advertisement
Agilent's stock closed at US$167.69 with a trading volume of 169,412 shares.
The stock's last close represents a 16.1% increase over its 50-day moving average, indicating strong recent performance.
Bull case
The NovoStation's introduction could strengthen Agilent's position in a growing market, potentially leading to increased sales and market share.
Bear case
Investors should be aware of potential competition in the automated sample preparation market, which could affect Agilent's growth prospects.
Agilent Launches NovoStation for Flow Cytometry
Advertisement
Agilent Technologies Inc has unveiled its NovoStation Sample Preparation System, designed to automate workflows related to flow cytometry. This system aims to streamline the sample preparation process, essential for various laboratory applications, potentially enhancing both efficiency and accuracy. The announcement comes as Agilent's stock closed at US$167.69, reflecting a notable 1-month increase of 16.1% and a strong position within its 52-week range of US$108.14 – US$163.75.
Stock Performance Insights
Following the announcement, Agilent's stock closed at US$167.69, with a trading volume of 169,412 shares, significantly higher than its 20-day average volume of 136,000 shares. The stock has shown robust performance, with a year-to-date increase of approximately 25%. It is currently at 107% of its 52-week range and is trading well above its 50-day moving average of US$144.43 and its 200-day moving average of US$131.50. The stock has a P/E ratio of 29.67, indicating a valuation that reflects investor confidence.
Future Developments to Monitor
As Agilent continues to innovate in the healthcare sector with the launch of the NovoStation, investors should watch the market response to this new product. Analysts have set an average target price of US$174.95, suggesting an implied move to target of 4.3%. Additionally, tracking any competitive developments in automated sample preparation technologies will be crucial for assessing Agilent's market position moving forward, as the company seeks to maintain its growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
